Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant Recipients
Benzinga Newsdesk 16 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the company’s clinical assay.
iMDx seeks to deliver a best-in-class molecular diagnostic test kit, to expand and improve testing access for kidney transplant patients, which it anticipates will deliver new value in the estimated $3 billion addressable market for regulated transplant rejection testing.
More on IMDX
Analyst ratings Benzinga
Lake Street Maintains Buy on Insight Molecular, Lowers Price Target to $9Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and lowers the price target from $12 to $9.
